Detalhe da pesquisa
1.
Antibody-drug conjugates in lung and breast cancer: current evidence and future directions-a position statement from the ETOP IBCSG Partners Foundation.
Ann Oncol
; 2024 Apr 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-38648979
2.
Translational insights and overall survival in the U31402-A-U102 study of patritumab deruxtecan (HER3-DXd) in EGFR-mutated NSCLC.
Ann Oncol
; 35(5): 437-447, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38369013
3.
Molecular markers of metastatic disease in KRAS-mutant lung adenocarcinoma.
Ann Oncol
; 34(7): 589-604, 2023 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-37121400
4.
Dissecting the clinicopathologic, genomic, and immunophenotypic correlates of KRASG12D-mutated non-small-cell lung cancer.
Ann Oncol
; 33(10): 1029-1040, 2022 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-35872166
5.
ESMO expert consensus statements on the management of EGFR mutant non-small-cell lung cancer.
Ann Oncol
; 33(5): 466-487, 2022 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-35176458
6.
Ultra-deep next-generation sequencing of plasma cell-free DNA in patients with advanced lung cancers: results from the Actionable Genome Consortium.
Ann Oncol
; 30(4): 597-603, 2019 04 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30891595
7.
Plasma HPV cell-free DNA monitoring in advanced HPV-associated oropharyngeal cancer.
Ann Oncol
; 29(9): 1980-1986, 2018 09 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30010779
8.
CNS response to osimertinib in patients with T790M-positive advanced NSCLC: pooled data from two phase II trials.
Ann Oncol
; 29(3): 687-693, 2018 03 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29293889
9.
SELECT-2: a phase II, double-blind, randomized, placebo-controlled study to assess the efficacy of selumetinib plus docetaxel as a second-line treatment of patients with advanced or metastatic non-small-cell lung cancer.
Ann Oncol
; 28(12): 3028-3036, 2017 Dec 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29045535
10.
Dacomitinib versus erlotinib in patients with EGFR-mutated advanced nonsmall-cell lung cancer (NSCLC): pooled subset analyses from two randomized trials.
Ann Oncol
; 27(3): 423-9, 2016 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-26768165
11.
Impact of KRAS codon subtypes from a randomised phase II trial of selumetinib plus docetaxel in KRAS mutant advanced non-small-cell lung cancer.
Br J Cancer
; 113(2): 199-203, 2015 Jul 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-26125448
12.
Targeting HER2 aberrations as actionable drivers in lung cancers: phase II trial of the pan-HER tyrosine kinase inhibitor dacomitinib in patients with HER2-mutant or amplified tumors.
Ann Oncol
; 26(7): 1421-7, 2015 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-25899785
13.
A randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC).
Ann Oncol
; 26(5): 894-901, 2015 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-25722381
14.
Clinical benefit of continuing ALK inhibition with crizotinib beyond initial disease progression in patients with advanced ALK-positive NSCLC.
Ann Oncol
; 25(2): 415-22, 2014 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-24478318
15.
Revisiting the relationship between tumour volume and diameter in advanced NSCLC patients: An exercise to maximize the utility of each measure to assess response to therapy.
Clin Radiol
; 69(8): 841-8, 2014 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-24857677
16.
Combined effect of ALK and MEK inhibitors in EML4-ALK-positive non-small-cell lung cancer cells.
Br J Cancer
; 106(4): 763-7, 2012 Feb 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-22240786
17.
Dacomitinib versus erlotinib in patients with EGFR-mutated advanced nonsmall-cell lung cancer (NSCLC): pooled subset analyses from two randomized trials.
Ann Oncol
; 27(7): 1363, 2016 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-27240994
18.
Osimertinib plus platinum-pemetrexed in newly diagnosed epidermal growth factor receptor mutation-positive advanced/metastatic non-small-cell lung cancer: safety run-in results from the FLAURA2 study.
ESMO Open
; 6(5): 100271, 2021 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-34543864
19.
Improving the yield of circulating tumour cells facilitates molecular characterisation and recognition of discordant HER2 amplification in breast cancer.
Br J Cancer
; 102(10): 1495-502, 2010 May 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-20461092
20.
MET increased gene copy number and primary resistance to gefitinib therapy in non-small-cell lung cancer patients.
Ann Oncol
; 20(2): 298-304, 2009 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-18836087